Achille Manirakiza: Rethinking Breast Cancer Risk and Early Detection in Women Under 50
Achille Manirakiza/LinkedIn

Achille Manirakiza: Rethinking Breast Cancer Risk and Early Detection in Women Under 50

Achille Manirakiza, Clinical Oncology Specialist, Research Director at King Faisal Hospital Rwanda, shared on LinkedIn:

“Glad to have contributed to a new review, out in Nature Reviews Clinical Oncology on early-onset breast cancer (diagnosed at age< 50).

Women under 50 now account for nearly a third of breast cancer diagnoses worldwide, and many are diagnosed before they’re eligible for routine screening.

We looked at what drives risk in this population. Inherited variants in genes like BRCA1, BRCA2, and TP53 are much more common in younger patients, found in roughly 35–40% of women diagnosed at 30 or younger. Ancestry, tumour subtype, reproductive history, and lifestyle shape risk too, and most current risk models were built on women of European ancestry, so they often miss variants in under-represented populations.

The central argument is that age alone is a poor measure of risk. Earlier detection only helps if family history, genetic testing, timely biopsy, and affordable treatment are linked.

Thanks to my co-authors for the work behind this.”

Read The Full Article.

Title: Global landscape of early-onset breast cancer: from understanding risk to precision prevention and cancer interception

Authors: Sulin Wu, Jason Semprini, Achille V. C. Manirakiza, Yonglan Zheng, Olufunmilayo I. Olopade

You can also read: FDA Approves Giredestrant Plus Everolimus: A New Treatment Option for ESR1-Mutated Advanced Breast Cancer

Achille Manirakiza: Rethinking Breast Cancer Risk and Early Detection in Women Under 50